Medicine
Yorvipath 420 mcg/1.4 mL injection
Yorvipath 420 mcg/1.4 mL injection is a prescription medicine containing Palopegteriparatide for subcutaneous use, marketed by Ascendis Pharma Endocrinology, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store away from heat. Keep YORVIPATH in the packaging to protect from light…
Key facts
- Active ingredient (INN)
- Palopegteriparatide
- Brand
- Yorvipath
- Strength
- 420 mcg/1.4 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 2 boxes of 1.4 mL
- Marketing authorisation holder
- Ascendis Pharma Endocrinology
- Manufacturer
- Ascendis Pharma Endocrinology
- Origin register
- US FDA, United States
- Storage
- Store away from heat. Keep YORVIPATH in the packaging to protect from light. After each use, remove the needle and put the pen cap on to protect from light.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- H05AA Calcium balance medicines, subgroup H05A, subgroup H05AA
- HS code (indicative)
- 3004.39Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 9 August 2024
- Identifiers
- DailyMed set ID a1fa23fd-c434-443e-9a17-5750578c8602NDC 73362-102Application NDA216490
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 2 box in 1 carton / 1 syringe in 1 box / 1 cartridge in 1 syringe / 1.4 mL in 1 cartridge | 73362-102-01 | Ascendis Pharma, Endocrinology | 9 August 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Palopegteriparatide
Clinical summary
Palopegteriparatide is a parathyroid hormone analog indicated for the treatment of hypoparathyroidism in adults. It is available as injection for subcutaneous use. MedsAcross supplies Palopegteriparatide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about PalopegteriparatideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Yorvipath prescribing information (Ascendis Pharma, Endocrinology) · U.S. National Library of Medicine, DailyMed
- Yorvipath: European public assessment report (EPAR) · European Medicines Agency
Need Yorvipath 420 mcg/1.4 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.